Abstract
We sought to determine whether administration of glycerol guaiacolate at an optimal biological dose inhibits human breast cancer cell growth. Human breast cancer MCF-7 and ZR-75-1 cells were treated with glycerol guaiacolate and the therapeutic efficacy and biological activity of this drug was investigated on breast cancer cell growth. MCF-7 cells were injected into the mammary fat pad of overectamized female athymic nude mice. Ten days later, animals were treated with daily intraperitoneal injections of glycerol guaiacolate for six weeks. Tumor size and volume was monitored and immunohistochemical analysis on MUC1, p21 and ki-67 was performed. Glycerol guaiacolate decreased breast cancer cell growth in a dose-dependent manner, decreased cell migration, and caused G1 cell cycle arrest. Our results demonstrate that glycerol guaiacolate inhibits MUC1 protein and mRNA expression levels and significantly increased p21 expression in human breast cancer cells as well as induced PARP cleavage. Similarly, glycerol guaiacolate inhibited breast tumor growth in vivo as well as enhanced p21 expression and decreased breast tumor cell proliferation (ki-67 expression). Collectively, our results demonstrate that glycerol guaiacolate decreased MUC1 expression and enhanced cell growth inhibition by inducing p21 expression in breast cancer cells. These findings suggest that glycerol guaiacolate may provide a novel and effective approach for the treatment of human breast cancer.
Keywords: Glycerol guaiacolate, MUC1, Breast cancer
Anti-Cancer Agents in Medicinal Chemistry
Title: Blockade of MUC1 Expression by Glycerol Guaiacolate Inhibits Proliferation of Human Breast Cancer Cells
Volume: 10 Issue: 8
Author(s): J.S. Smith, J. Colon, R. Madero-Visbal, B. Isley, S.D. Konduri and C.H. Baker
Affiliation:
Keywords: Glycerol guaiacolate, MUC1, Breast cancer
Abstract: We sought to determine whether administration of glycerol guaiacolate at an optimal biological dose inhibits human breast cancer cell growth. Human breast cancer MCF-7 and ZR-75-1 cells were treated with glycerol guaiacolate and the therapeutic efficacy and biological activity of this drug was investigated on breast cancer cell growth. MCF-7 cells were injected into the mammary fat pad of overectamized female athymic nude mice. Ten days later, animals were treated with daily intraperitoneal injections of glycerol guaiacolate for six weeks. Tumor size and volume was monitored and immunohistochemical analysis on MUC1, p21 and ki-67 was performed. Glycerol guaiacolate decreased breast cancer cell growth in a dose-dependent manner, decreased cell migration, and caused G1 cell cycle arrest. Our results demonstrate that glycerol guaiacolate inhibits MUC1 protein and mRNA expression levels and significantly increased p21 expression in human breast cancer cells as well as induced PARP cleavage. Similarly, glycerol guaiacolate inhibited breast tumor growth in vivo as well as enhanced p21 expression and decreased breast tumor cell proliferation (ki-67 expression). Collectively, our results demonstrate that glycerol guaiacolate decreased MUC1 expression and enhanced cell growth inhibition by inducing p21 expression in breast cancer cells. These findings suggest that glycerol guaiacolate may provide a novel and effective approach for the treatment of human breast cancer.
Export Options
About this article
Cite this article as:
Smith J.S., Colon J., Madero-Visbal R., Isley B., Konduri S.D. and Baker C.H., Blockade of MUC1 Expression by Glycerol Guaiacolate Inhibits Proliferation of Human Breast Cancer Cells, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (8) . https://dx.doi.org/10.2174/187152010794473984
DOI https://dx.doi.org/10.2174/187152010794473984 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Pharmacological Evaluation of Maleopimaric N-arylimides: Identification of Novel Proapoptotic Agents
Anti-Cancer Agents in Medicinal Chemistry Melanocortin-4 Receptor Antagonists as Potential Therapeutics in the Treatment of Cachexia
Current Topics in Medicinal Chemistry Study of Antioxidant, Antiproliferative and DNA Damage Protecting Activities of <i>Cinnamomum</i> cassia Extracts Obtained by Sequential Extraction
Recent Patents on Food, Nutrition & Agriculture New Developments in Targeted Analysis of Protein Posttranslational Modifications
Current Proteomics Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy Targeting Telomerase for Cancer Therapy
Current Cancer Therapy Reviews ADP-Ribosylated Proteins as Old and New Drug Targets for Anticancer Therapy: The Example of ARF6
Current Pharmaceutical Design Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology MicroRNA and HER2-overexpressing Cancer
MicroRNA Radiopharmaceuticals in Tumor Hypoxia Imaging: A Review Focused on Medicinal Chemistry Aspects
Anti-Cancer Agents in Medicinal Chemistry Anti-tumor Therapeutic Molecules that Target the Programmed Cell Death Machinery
Mini-Reviews in Medicinal Chemistry Mechanisms of ERK1/2 Regulation by Seven-Transmembrane-Domain Receptors
Current Pharmaceutical Design Current Molecularly Targeting Therapies in NSCLC and Melanoma
Anti-Cancer Agents in Medicinal Chemistry Development and Applications of Optical Imaging Techniques in Cancer Diagnosis: Diffuse Optical Tomography and Microendoscopy
Current Medical Imaging Chitosan Nanoparticles as a Novel Drug Delivery System: A Review Article
Current Drug Targets Inhibition of Aromatase (AR) by Benzyl Azole-Based Compounds
Letters in Drug Design & Discovery Metabolomics-based Approach to Pharmacotherapy Personalization: Advantages and Limitations
Current Pharmacogenomics and Personalized Medicine Deregulation of the Mitochondrial Apoptotic Machinery and Development of Molecular Targeted Drugs in Acute Myeloid Leukemia
Current Cancer Drug Targets Recent Progress of Novel Steroid Derivatives and Their Potential Biological Properties
Mini-Reviews in Medicinal Chemistry Notch Signaling: A Potential Therapeutic Target in Prostate Cancer
Current Cancer Drug Targets